{
  "docId": "019f6b8f-1840-747c-b048-7afedf31e31d",
  "docSlug": "jarvis-ey-how-fit-is-your-capital-allocation-strategy",
  "documentTitle": "EY How fit is your capital allocation strategy",
  "authorId": "ey-how-fit-is-your-capital-allocation-strategy",
  "authorName": null,
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": null,
  "aspectRatio": null,
  "pageNumber": 15,
  "pageCount": 24,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The slide features a report cover image titled 'Cash on prescription'.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019f6b8f-1840-747c-b048-7afedf31e31d/15",
  "deckHref": "/decks/019f6b8f-1840-747c-b048-7afedf31e31d",
  "deckJsonHref": "/decks/019f6b8f-1840-747c-b048-7afedf31e31d.json",
  "deckAnchorHref": "/decks/019f6b8f-1840-747c-b048-7afedf31e31d#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.38,
        "x": 0.07,
        "y": 0.23
      },
      "kind": "image",
      "text": "Report cover: Cash on prescription, Pharmaceutical companies and working capital management 2015",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1814567-bf62-4894-89bd-243c53409d7b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.5,
        "y": 0.2
      },
      "kind": "list",
      "text": "Big pharma companies have as much as US$50billion in excess working capital (WC)\nBig pharma's 2014 WC performance stronger than in 2007, but ...\n... WC varies widely overall along the metrics we track (e.g., DSO, DIO, DPO and C2C)\nIndividual opportunities for improvement, especially by adopting practices of leading WC performers in other industries",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa2ed83f-9582-4d0d-b5b1-23be0cbe702c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Working capital key to development of more cost-effective, less risky business models",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96e40a3f-afc2-4466-be70-a07319343ac1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "36d6da6e-c40f-40ef-90dd-096a70bb59db",
      "evidence": "Big pharma companies have as much as US$50billion in excess working capital (WC)",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 7,
      "beatId": "2ee61659-cd45-4e64-8c84-7f31031fa91a",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document provides data and analysis to support its claims.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}